INTRODUCTION
Even when targeted therapy results in cancer remission, relapse can emerge from rare drug-resistant cells (Bozic et al., 2013; Hughes and Andersson, 2015; McGranahan and Swanton, 2017) . Indeed, mathematical modeling predicts that clinically detectable, treatment-naive cancers nearly always harbor one or more rescue subclones (RSCs) equipped to seed relapse (Bozic et al., 2013; Diaz et al., 2012) . In practice, RSC populations can be vanishingly small, precluding routine RSC detection within clinical specimens until relapse is well underway. Moreover, the detection and enumeration of unique RSCs at relapse can be confounded by parallel evolution. For example, because RSCs typically are identified by their rescue mutations, RSCs falsely appear clonally related when they independently acquire identical, highly recurrent rescue mutations. As such, how evolutionary pressures act in the pre-treatment setting to influence the number, size, and turnover of discrete RSC populations remains obscure.
Targeted therapies typically exploit a phenomenon termed oncogene addiction, wherein cancer cells show exquisite dependence on an aberrantly activated signaling pathway for survival and/or proliferation (Weinstein, 2002) . Inversely, diverse basic and clinical research findings indicate that cancer cells become impaired not only when challenged by oncogene withdrawal but also when confronted by oncogene overdose. Overexpressing potent oncogenes in untransformed cells paradoxically triggers proliferation arrest or cell death in cell culture and in mouse models (Nieto et al., 2017; Sarkisian et al., 2007; Serrano et al., 1997) . Similarly, certain cancers almost never acquire two driver mutations that potently activate the same oncogenic signaling pathway, perhaps because concerted action of strong activating events triggers overdose Unni et al., 2015) . In the clinic, sensitivity to excessive oncogenic signaling likely explains why pharmacologic doses of gonadal hormones paradoxically served as effective treatment for hormone-dependent breast cancers before the advent of modern anti-hormonal drugs (Haddow et al., 1944; Jordan and Ford, 2011) . More recently, oncogene overdose has been invoked to explain why some cancers, after adapting to potent targeted therapy, paradoxically depend upon continued drug treatment for maintenance and growth (Amin et al., 2015a (Amin et al., , 2015b Das Thakur et al., 2013; Sun et al., 2014) . Intriguingly, preclinical models of melanoma, lymphoma, and prostate cancer have led to clinical trials aimed at exploiting oncogene overdose for therapeutic gain in patients (Amin et al., 2015a; Schweizer et al., 2015) . Despite these advances, it remains unclear whether and how oncogene overdose shapes the evolution of incipient RSCs prior to treatment.
To model targeted therapy of breast cancer, we previously engineered mice for reversible activation of oncogenic Wnt signaling. In female inducible Wnt1 (iWnt) mice, doxycycline (Dox)-induced expression of a Wnt1 transgene leads to the stochastic onset of Wnt-driven mammary carcinomas. iWnt tumors regress upon simulated targeted therapy (withdrawal of inducerdependent Wnt1 expression) and then relapse later with rescue mutations that restore Wnt signaling (Debies et al., 2008; Gunther et al., 2003) . Most iWnt relapses acquire one of two rescue mutations: either an activating mutation in the downstream Wnt transducer b-catenin (encoded by Ctnnb1; hereafter b-Cat) or a mutation corrupting the rtTA gene switch (enabling Dox-independent expression of the Wnt1 transgene; Cleary et al., 2014) . These rescue mutations are highly recurrent, which limits detection of discrete RSCs. When reconstructing the clonal evolution of human cancers, mapping distinct, functionally equivalent tumor suppressor gene mutations to spatially separated tumor sites can reveal discrete subclones evolving in parallel (Gerlinger et al., 2012; Juric et al., 2015) . To render clonal evolution in the iWnt model more amenable to genetic analysis, we introduced a germline Apc Min allele (Moser et al., 1993) , thereby inactivating one copy of the Adenomatous polyposis coli (Apc) tumor suppressor gene that normally restrains Wnt signaling. We reasoned that iWnt/Apc Min/+ tumors should be sensitized to relapse via somatic, inactivating second-hit Apc mutations, which might inform on RSC evolution in two key ways. First, selection for Apc second hits ought to broaden the range of functionally equivalent rescue mutations with which to distinguish independent RSCs. Second, the precise location of second-hit Apc mutations ought to provide a crucial readout of the level of Wnt signaling favored at relapse. In human colorectal cancers, second-hit APC mutations are contingent upon the first APC hit (whether inherited or sporadic) in a manner that selects for maintaining some residual APC-mediated restraint on Wnt signaling (Albuquerque et al., 2002; Rowan et al., 2000) . Similarly, studies employing either allelic series of targeted Apc mutations or inducible Apc knockdown in mice consistently show that genotypes conferring graded reductions in Apc function specify graded increases in Wnt signaling (Buchert et al., 2010; Dow et al., 2015; Kielman et al., 2002; Premsrirut et al., 2011) . Most notably, hypomorphic mutations that create premature stop codons in the Apc mammary tumor mutation cluster region (Apc mmcr ; ranging from Apc codons 1,512-1,580; Figure 1A ), when paired with a near null Apc allele (e.g., Apc
Min ), specify a sub-maximum level of Wnt pathway activation that is uniquely suited to initiating mammary carcinogenesis (Bakker et al., 2013; Gaspar et al., 2009; Kuraguchi et al., 2009; Toki et al., 2013) . Whether such cancers, once established, are constrained to maintain sub-maximum Wnt signaling during tumor progression remains unknown. (Haigis and Dove, 2003) , consistent with selection for complete loss of the Apc-mediated restraint on Wnt signaling in intestinal tumor cells ( Figure S1B ). Wnt1 transgene expression, which was robust in primary iWnt/ Apc Min/+ mammary tumors, dropped to nearly undetectable levels at relapse, suggesting second-hit Apc mmcr rescue mutations are sufficient for Wnt pathway reactivation ( Figure 1D ). Next, we tested whether rescue mutations generating an Apc Min/mmcr tumor cell genotype confer sub-maximum Wnt pathway activation by performing b-cat immunohistochemistry on tissue and tumor sections. Stabilization of b-cat culminates in cytosolic accumulation and nuclear translocation, which serve as classic hallmarks of activated Wnt signaling. In the intestine, weak, membrane-associated b-cat expression in normal epithelium contrasted with strong nuclear-localized expression in adenomas, as others have described ( Figure S2 ). In both normal mammary gland and tumors arising in the MMTV-Myc transgenic mouse model (Stewart et al., 1984) , only weak membrane-associated b-cat was detected, consistent with negligible Wnt pathway activation ( Figure 1E ). By comparison, mammary tumors from iWnt/Apc Min/+ mice consistently stained more strongly for b-cat, with evidence for modest cytosolic accumulation as well as weak nuclear-localized staining in some cells. Notably, despite the cell-to-cell variability evident within each tissue section, the overall level and pattern of b-cat expression was remarkably conserved across primary and relapsed mammary tumors, suggesting selection for a preferred Wnt pathway activation level. Confirming that this preferred signaling level resides below that which is conferred by complete Apc loss of function, the lone mammary tumor relapse in our set that underwent Apc LOH showed strong, nuclear-localized b-cat expression on par with that observed in intestinal adenomas (Figures 1E and S2) . Why this relapse was unique in evading selection for the recurring Apc Min/mmcr tumor cell genotype is unclear.
RESULTS

Relapse after
Nonetheless, in sum, our findings underscore strong selection for a sub-maximum Wnt signaling window during mammary tumorigenesis, as others have proposed. Extending this concept, we find that selection for this signaling window is conserved across diverse Wnt pathway-driven mammary tumor models, because relapses arising in iWnt/Apc Min/+ mice resemble primary mammary tumors arising in carcinogenexposed Apc Min/+ mice (Keller et al., 2016) derived from polyclonal relapses harbored a single predominant Apc mmcr rescue mutation, indicating that polyclonal relapses tended to be conglomerates of macroscopic, primarily monoclonal RSCs ( Figure S3 ). However, we cannot rule out the possibility that low-prevalence RSCs lacking Apc mmcr mutations sometimes contribute as admixed subclones.
To determine whether RSCs derive from stable subpopulations of tumor cells lurking within primary tumor explants prior to Wnt withdrawal, RSC maps were generated for a set of relapses arising within two independent iWnt/Apc Min/+ tumor lineages, each propagated through multiple generations of serial passage on Dox-treated hosts ( Figure 3A Figures 3B and S3 ). Analysis of a second independent tumor lineage (hereafter lineage B) likewise failed to reveal pervasive, long-lived RSCs ( Figure 3B , right panels). Again, most rescue mutations identified in lineage B were unique (17 of 25; 68%), and novel rescue mutations continued to appear in late-passage tumors. Moreover, comparing rescue mutations across explant generations showed that a subset of mutations that recurred went absent from one or more intervening passages, suggesting they likely arose independently ( Figure 3B ).
Compared with explants from lineage A, explants from lineage B on average showed reduced relapse-free survival following Wnt withdrawal as well as increased polyclonality at relapse (i.e., more RSCs per relapse) detected by MRS analysis (Figure 3C) . The mechanism(s) underlying these differences remain unknown but presumably stem from traits acquired during the clonal evolution of each ancestral primary tumor. In any event, the distinct behavior of these lineages offers an intriguing link between increased polyclonality and more rapid onset of tumor escape.
Rapid Turnover of RSCs Generated by Mutagen Exposure Next, we devised a strategy for detecting turnover of RSCs during growth of iWnt/Apc Min/+ tumors. When exploring the range of rescue mutations capable of subverting targeted therapy, Sanger sequencing in each segment of a representative relapse. The aggregate MRS analysis was used to construct a color-coded subclone map, in which segments sharing the same rescue mutation are color matched. Split segments denote detection of two distinct rescue mutations co-residing in a single segment. The subclone map is depicted in ''bivalve view'' such that folding the map at the dotted midline overlays the original 3 3 3 segmented halves in register.
researchers often employ accelerated mutagenesis protocols, wherein treatment of a drug-sensitive tumor cell population is preceded by exposure to a potent mutagen. Although mutations are introduced genome-wide, subsequent drug treatment strongly selects for rescue mutations that drive RSC outgrowth (Brammeld et al., 2017 Figure 4A ). Compared with unexposed control tumors, ENU exposure 2 days before Wnt withdrawal (day À2 ENU) dramatically hastened relapse onset and increased the number of RSCs per relapse detected via MRS, as expected ( Figure 4B ). Indeed, the number of RSCs arising after day À2 ENU exceeded the number of tumor segments analyzed, meaning that individual tumor segments themselves typically were polyclonal ( Figure S4 ). Paradoxically, highly polyclonal tumor segments comprised of multiple Apc mmcr mutant RSCs appeared wild-type when initially assessed by Sanger sequencing, because this low-sensitivity technique only detects an allelic variant that reaches a minimum prevalence of about 10%-15%, which corresponds to an RSC that reaches a minimum prevalence of 20%-30% of the cells analyzed (assuming Apc mmcr mutations are heterozygous and unperturbed by copy number variation). By contrast, analyzing Apc mmcr alleles by HTS permitted detection of mutant alleles above a threshold of about 0.3% prevalence, which enabled detection of as many as 9 distinct, low-prevalence Apc mmcr mutant RSCs residing in a single relapse segment ( Figure S4 ). We confirmed that these day À2 ENU relapse segments were indeed highly polyclonal by two additional means. In one strategy, relapse segments, which typically measured 3-5 mm in diameter, were first subdivided into sub-millimeter fragments before preparing genomic DNA (gDNA) templates for analysis. Subsequent Sanger sequencing of PCR-amplified Apc mmcr alleles detected multiple rescue mutations distributed among the subdivided tumor fragments ( Figure S5 ). In a second strategy, bulk gDNA templates from putative polyclonal segments were used to generate PCR-amplified Apc mmcr alleles as before, but alleles were subcloned prior to Sanger sequencing. Again, rescue mutations that eluded detection on bulk analysis were detected readily after subcloning ( Figure S5 ), indicating these day À2 ENU tumor segments are indeed composites of numerous minute RSCs. Remarkably, moving ENU exposure from day À2 to day À7 significantly reduced ENU's impact on both relapse-free survival and RSCs per relapse, consistent with rapid dropout of short-lived, ENU-initiated RSCs during the added days preceding Wnt withdrawal ( Figure 4B ). In a parallel arm of this experiment, an additional set of tumors was subjected to an interrupted Wnt withdrawal schedule to simulate a drug-free break in the midst of targeted therapy (Figure 4A) . Here, after day À7 ENU exposure, Wnt withdrawal was maintained during two weeks of tumor regression and then transiently reversed until tumors regrew to their original size, whereupon Wnt withdrawal was reinstated for the remainder of the experiment. Interrupted Wnt withdrawal yielded a trend toward prolonged relapse-free survival and generated significantly fewer RSCs per relapse ( Figure 4B ), consistent with RSC dropout resuming during Wnt pathway reactivation and tumor re-growth.
Examination of Apc mmcr mutation spectra confirmed that ENU exposure seeded relapse by generating second-hit Apc rescue mutations. Unexposed relapses yielded a mutation spectrum dominated by indels and single nucleotide variants (SNVs) at G:C base pairs, mirroring the spectrum of spontaneous, somatic Apc mmcr mutations described previously (Kuraguchi et al., 2009 ).
By contrast, ENU exposure shifted the spectrum away from indels toward SNVs at A:T base pairs ( Figure 4C ), matching known ENU mutation patterns (Jansen et al., 1994b; Keller et al., 2016) . Concordantly, replacing ENU with the related mutagen N-methyl-N-nitrosourea (MNU) similarly hastened relapse and increased RSCs per relapse while generating a distinct, MNU-specific mutation spectrum (Figures 4B and 4C) . Notably, despite MNU's known propensity to induce G:C to A:T base substitutions (Jansen et al., 1994a; Westcott et al., 2015) , sense-strand G > A SNVs were completely absent from our Apc mmcr -derived mutation spectrum, reflecting a genetic coding constraint. Specifically, the Apc mmcr lacks a TGG codon, the only codon capable of converting to a stop codon via a G > A SNV. We hypothesized that this coding constraint, coupled with the constraint to restore sub-maximum Wnt signaling, might channel sense-strand G > A SNVs toward rescue mutations in alternative target genes. Indeed, whereas ENU-exposed relapses harbored an Apc mmcr rescue mutation in nearly every tumor segment ( Figure S5 ), fully one-third of MNU-exposed relapse segments lacked an Apc mmcr mutation (35 of 105; 33%), and a subset of these segments instead harbored b-Cat or rtTA rescue mutations, which invariably were sense-strand G > A SNVs ( Figure 4D ). (C) Apc mmcr rescue mutation spectra obtained under various exposure conditions. Unexposed, n = 109 Apc mmcr mutations; day À2 ENU, n = 66; day À7 ENU, n = 72; day À7 ENU/interrupted withdrawal, n = 44; day À7 MNU, n = 44. (D) Alternative G > A rescue mutations detected in MNU-exposed relapse segments that lack an Apc mmcr rescue mutation.
*p < 0.05; **p < 0.01; ***p < 0.001; t test.
quickly and invariably acquired Apc mmcr rescue mutations instead of b-Cat mutations ( Figures 5A and 5B ), as did a subset of MNU-exposed tumors (see below). Because a single intact Apc allele normally suffices to restrain Wnt signaling, we searched for collaborating second-hit Apc mutations. Remarkably, these Apc mmcr mutant relapses nearly always carried a second somatic inactivating mutation further upstream in Apc (15 of 16 tumors; 94%; Figure 5C ). We refer to these somatic upstream Apc mutations as ''Min-like,'' because they encode truncated proteins similarly devoid of all (or nearly all) of the seven 20-amino-acid repeats implicated in b-catenin downregulation. Several observations suggest that mutagen exposure may generate biallelic Apc inactivation through a complex mutational process involving quasi-synchronous Apc hits, rather than sequential, metachronous Apc hits. First, neither Apc hit on its own is expected to provide a sizable selective advantage that drives clonal expansion, making sequential acquisition of Apc hits statistically unlikely. Second, four relapses were found to be comprised of two distinct RSCs, each carrying a unique Apc Min-like/mmcr genotype. Subclone maps from these relapses showed that neighboring tumor segments never shared one Apc hit, but not the other, as might be expected to occur if hits accrued metachronously ( Figure S6A ). Third, when the mutations that generated Apc mmcr versus Apc Min-like alleles were analyzed separately, both mutation sets yielded spectra attributable to ENU exposure, despite ENU's short-lived mutagenic activity in vivo (Probst and Justice, 2010; Figure S6B relapses. Crucially, these relapses converge on Apc allele pairs that, in sum, retain 3 or 4 b-catenin degradation domains ( Figure 5C ), again indicating robust selection for a preferred Wnt signaling level conducive to mammary tumor maintenance (Bakker et al., 2013) . Concordantly, relapses that acquired biallelic mutations culminating in the Apc Min-like/mmcr tumor cell genotype showed sub-maximum b-cat immunostaining on par with their antecedent primary tumors ( Figure S2 ). Whereas MNU-exposed iWnt/Apc +/+ tumors relapsed even faster than their ENU-exposed counterparts ( Figure 5A ), they only rarely relapsed with biallelic Apc rescue mutations (3 of 15 tumors; 20%), likely due to the coding constraints discussed above that disfavor acquisition of MNU-induced nonsense mutations within the Apc mmcr . Instead, MNU-exposed relapses often acquired b-Cat or rtTA rescue mutations ( Figure 5B ), which invariably were sense-strand G > A SNVs, as before ( Figure 5D ). Together, these findings underscore how exposure-specific mutation spectra, when filtered through narrow signaling requirements and coding constraints, can bias rescue mutations toward ''preferred'' driver genes with remarkable specificity (Keller et al., 2016) .
Negative Selection of RSCs under Conditions Predicted to Drive Wnt Signaling Overdose
Returning to iWnt/Apc Min/+ tumors, we considered whether the rapid dropout of mutagen-initiated RSCs prior to Wnt withdrawal might occur by neutral drift rather than by counter-selection against Wnt signaling overdose. To test whether parental tumor cells compete neutrally with RSC cells, we compared their relative clonal expansion in a competitive tumor reconstitution assay. Single-cell suspensions were prepared concurrently from three freshly harvested, sibling iWnt/Apc Min/+ tumor specimens (schematized in Figure 6 ). P cells (denoting parental) were prepared from a Wnt-dependent primary tumor explant. R1 and R2 cells (denoting relapse) were prepared from distinct segments of a putative polyclonal relapse, which arose from a sibling explant during Wnt withdrawal. R1 and R2 cells were generated from antipodal segments to maximize the likelihood of sampling distinct RSC populations. Then tumors were reconstituted in the mammary fat pads of syngeneic, Dox-treated host mice by injecting each cell population individually (P-only, R1-only, and R2-only control injections) or by co-injecting admixed populations. Specifically, R2 cells were competed against both R1 cells (R1 + R2 injections) and P cells (P + R2 injections). Due to limiting tumor cell numbers, we did not compete R1 cells against P cells (i.e., P + R1 injections were not performed). Injections of all individual and admixed tumor cell populations yielded tumors that arose promptly and grew synchronously, permitting all necropsies and tumor harvests to be performed on the same day. Finally, MRS was performed on each reconstituted tumor to assess the contribution of individual subclones. Kuraguchi et al., 2006) . In summary, as schematized in Figure 7A , Tam treatment The cartoon at left depicts the experimental strategy for comparing clone contribution during competitive tumor reconstitution. Experimental results are depicted as subclone maps (color-coded 3 3 6 grids as in Figure 2 but with the bivalve ''fold'' rotated 90 degrees). Each map depicts the MRS analysis performed on a single reconstituted tumor (n = 4 for R1 + R2 co-injection; n = 8 for R2 + P co-injection). The key at top right indicates the color assignment for each Apc mmcr mutation. Upper panels: neutral competition between R1 and R2 relapse cell populations is shown. Subclone map analysis shows that the number of segments bearing R1-specific versus R2-specific mutant alleles was comparable to the number expected based on the ratio of R1:R2 cells within the injected admixture (no significant variation from expected clone contribution; p = 0.48; Fisher's exact test with Freeman-Halton extension; 5.5 segments rounded to 6.0; 49.5 rounded to 50). Lower panels: P cells outcompete R2 cells. The number of segments bearing R2-specific mutant alleles is significantly less than the number expected based on the ratio of R2:P cells within the injected admixture (p < 0. Figure 7A ). Tumor-bearing mice then were dosed with Tam to initiate tracing of both mammary and intestinal tumor cell clones while simultaneously inactivating the Apc CKO allele. In control mice, clones residing in both mammary tumors and intestinal tumors at day 2 of the trace comprised mostly solitary labeled cells, which typically expanded to monochrome cell clusters at day 7, as expected. In experimental mice, tracing of intestinal tumor clones was unperturbed by the Apc CKO allele, but tracing of mammary tumor clones showed a marked reduction in labeled cells at day 2 and a near absence of labeled cells at day 7, indicating dropout of mammary, but not intestinal, tumor cell clones ( Figures 7B and  7C) . Concordantly, recombined Apc CKO alleles were detectable in these mammary tumors using a PCR-based assay (Kuraguchi et al., 2006) at day 2, but not at day 7 ( Figures S7D and S7E ). Thus, dropout of recombined tumor cells was highly context dependent, consistent with the lower Wnt signaling level window conducive to mammary versus intestinal tumor growth. Together, our clone competition and lineage-tracing studies strongly reinforce the causal link between oncogene overdose and clone dropout.
P-only injection yielded tumor segments lacking detectable
DISCUSSION
Potent targeted therapy triggers regression of oncogene-addicted cancers, but most patients relapse within months due to selection for rare tumor cells, which frequently carry rescue mutations that restore oncogenic signaling. Although rescue mutations often pre-exist drug treatment (Bhang et al., 2015; Diaz et al., 2012; Hata et al., 2016; Misale et al., 2012; Turke et al., 2010) , the evolutionary dynamics shaping drug-resistant RSC populations prior to targeted therapy remain obscure. Here, by mapping the clonal evolution of relapse in mouse models of breast cancer, we show that rescue mutations can impose collateral sensitivity to oncogene overdose, thereby driving potent negative selection prior to oncogene withdrawal. To make this observation, we developed mouse modeling strategies that enabled the detection of dozens of distinct, yet functionally equivalent, Apc mmcr rescue mutations, which unequivocally subvert Wnt withdrawal by acting as drivers of mammary cancer relapse. Notably, we defined experimental conditions in which simulated targeted therapy reliably culminates in polyclonal relapse, creating opportunities to model a commonly encountered clinical scenario (Burrell and Swanton, 2014) . Our overall methodology offers an alternative to performing tumor cell lineage tracing using barcoded retroviruses. Although barcoding offers a powerful means of monitoring subclonal lineages as they expand and contract through time (Bhang et al., 2015; Hata et al., 2016) , the tracing experiments are conducted using cell culture, and they require ex vivo labeling that may be inefficient and biased toward readily transduced subsets of tumor cells (Bystrykh and Belderbos, 2016) . Our analysis of the evolutionary dynamics underlying tumor growth suggests Wnt-driven mammary cancers may be useful for preclinical modeling of adaptive therapy. Whereas traditional cancer treatment protocols are designed to maximize tumor cell killing, adaptive therapy protocols are tailored to forestall tumor growth by exploiting sustained competition between treatmentsensitive and treatment-resistant tumor cell populations (Gatenby et al., 2009). The concept has shown promise in both preclinical breast cancer models (Enriquez-Navas et al., 2016) and a small-scale clinical trial for prostate cancer (Zhang et al., 2017) . Notably, adaptive therapy hinges on rescue mutations imposing a fitness cost during breaks in treatment. Wnt-dependent mammary cancers meet this requirement, because treatment-sensitive parental tumor cells consistently outcompeted treatment-resistant RSCs when simulated targeted therapy was withheld in both tumor reconstitution assays ( Figure 6 ) and in situ lineage-tracing studies (Figure 7) . Intriguingly, we saw preliminary evidence that simulating a ''treatment holiday'' in the midst of Wnt withdrawal offers clinical benefit. Compared with continuous Wnt withdrawal, interrupted Wnt withdrawal led to RSC dropout and a trend toward prolonged relapse-free survival ( Figures 4A and 4B) . Although the clinical benefit of this interrupted Wnt withdrawal protocol was modest, it should be noted that we applied it against cancers with elevated RSC burden (owing to prior ENU exposure) and tested only a single treatment break, arbitrarily scheduled to last two weeks. Future studies will test whether more durable control of Wnt-driven mammary cancers can be achieved by incorporating multiple treatment breaks, scheduled with evolutionary principles in mind. Our modeling approach ought to permit changes in RSC prevalence to be quantified during response to different adaptive therapy schedules. Monitoring competing tumor subsets through time may reveal strategies for directing clonal evolution along preferred trajectories that most effectively eradicate RSCs and/or block disease progression.
Our study illustrates how targeted therapy, by imposing precise selective pressure, can favor rescue mutations affecting a narrow range of genes, thereby rendering the evolutionary path to relapse predictable. That said, we found that subtle changes in exposure history led to dramatic shifts favoring rescue mutations in specific genes. In our accelerated mutagenesis studies, rescue mutations were induced by two mutagens, ENU and MNU, which bear striking structural similarity yet generate distinct patterns of DNA base substitutions (Jansen et al., 1994a (Jansen et al., , 1994b . When overlaid on genetic coding constraints, these mutagen-specific mutation patterns channeled rescue mutations to ''preferred'' driver genes with remarkable specificity ( Figures 4D and 5B ). These findings underscore how a cancer's own exposure history can inform efforts to predict the most favored genetic routes to relapse (Keller et al., 2016) . Our modeling sets the stage for dissecting mechanisms whereby clinically important mutagenic exposures, such as prior treatments with radiation or chemotherapy, dictate which rescue mutations emerge during subsequent targeted therapy.
Future work will address which cellular mechanism(s) act downstream of Wnt signaling overdose to limit outgrowth of RSCs. Previous studies have implicated either cell death pathways (Kong et al., 2017; Unni et al., 2015; Varmus et al., 2016) or proliferation arrest pathways (Das Thakur et al., 2013; Nieto et al., 2017; Sun et al., 2014) in restricting outgrowth of subclones challenged by oncogene overdose. Which cellular mechanisms come into play may vary depending on the tumor type examined and/or which tumor suppressor mechanisms have remained intact during tumor progression.
Our study has several important limitations that preclude direct translation to clinical settings. Because all of our observations derive from mouse models, species differences must be considered when extrapolating our findings to human cancers. In addition, it is worth noting that mutations activating the Wnt pathway have been observed only rarely in human breast cancer (Nik-Zainal et al., 2016) . Furthermore, we relied on a genetic simulation of targeted therapy, because clinically useful Wnt pathway inhibitor drugs remain under development. That said, by focusing on the Wnt pathway, we conducted our experiments in a uniquely detailed genetic framework, permitting mechanistic insights into the role of oncogene overdose in clonal evolution. Some of these insights are worth considering in the context of human cancer. For example, selection against overdose in treatment-naive cancers may help to explain why rescue mutations often reside within low-prevalence subclones prior to targeted therapy and why rescue subclone prevalence can drop during breaks in treatment (Siravegna et al., 2015) . In addition, our modeling predicts that some highly recurrent rescue mutations observed in the clinic may be common precisely because they elevate oncogenic signaling only modestly in the pre-treatment setting, thereby evading oncogene overdose. Whether clinically important rescue mutations likewise sensitize human cancer cells to oncogene overdose remains to be determined. If so, treatment strategies designed to exploit this vulnerability may help eliminate cancer subclones capable of seeding drug-resistant relapse.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
ACKNOWLEDGMENTS
We thank Aswathy Sebastian and Istvan Albert of the Penn State Bioinformatics Consulting Center for expert help with processing and analyzing of Illumina sequencing outputs. High-throughput sequencing was performed through the Penn State Genomics Core Facility (University Park, PA, USA). We thank members of the Gunther laboratory for critical review of the manuscript. This work was supported by grants from the National Cancer Institute (R01 CA152222 and R01 CA212584) and funding received from the benefactors of the Jake Gittlen Laboratories for Cancer Research. Animal housing was provided through a facility constructed with support from a Research Facilities Improvement Grant (C06 RR-15428-01) from the National Center for Research Resources.
AUTHOR CONTRIBUTIONS
Conceptualization, R.R.K. and E.J.G.; Methodology, R.R.K. and E.J.G.; Investigation, R.R.K.; Writing -Original Draft, R.R.K. and E.J.G.; Writing -Review and Editing, R.R.K. and E.J.G.; Visualization, R.R.K. and E.J.G.; Funding Acquisition, E.J.G.
DECLARATION OF INTERESTS
Toki, H., Inoue, M., Motegi, H., Minowa, O., Kanda, H., Yamamoto, N., Ikeda, A., Karashima, Y., Matsui, J., Kaneda, H., et al. (2013) . Novel mouse model for Gardner syndrome generated by a large-scale N-ethyl-N-nitrosourea mutagenesis program. Cancer Sci. 104, 937-944.
Turke, A.B., Zejnullahu, K., Wu, Y.L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) . Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88.
Unni, A.M., Lockwood, W.W., Zejnullahu, K., Lee-Lin, S.Q., and Varmus, H. (2015) . Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. eLife 4, e06907. 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed and will be fulfilled by the Lead Contact, Edward Gunther (ejg12@psu.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Mice were housed at the Pennsylvania State University College of Medicine and permitted unrestricted access to food and water. All experimental protocols were approved by the Pennsylvania State University College of Medicine's Institutional Animal Care and Use Committee. Apc Min , UBC-Cre ERT , and Confetti mice were obtained from Jackson Laboratories (C57BL/6J-Apc Min /J stock no. 002020), (B6.Cg-Tg(UBC-cre/ERT2)1Ejb/1J stock no. 007001), (Gt(ROSA)26Sor tm1(CAG-Brainbow2.1)Cle /J stock no. 137331). MMTV-rtTA/TetO-Wnt1 mice were obtained by crossing male C57BL/6J to female MMTV-rtTA/TetO-Wnt1 for a consistent F 1 FVB/N-C57BL/6J genetic background. For doxycycline (dox) treatment, standard mouse chow was replaced with chow containing 2 g/kg drug (Bio Serv). Genotyping was performed via PCR using isolated genomic DNA from tail clips. UBC-Cre ERT , Confetti, and Apc CKO/CKO as described from source. MMTV-rtTA and TetO-Wnt1 PCR using transgene specific primers (available upon request).
Apc
All hosts were female F 1 FVB/N-C57BL/6J mice.
METHOD DETAILS
Primary tumor initiation, explants, and relapse MMTV-rtTA/TetO-Wnt1 primary tumors and MMTV-rtTA/TetO-Wnt1/Apc min primary tumors were initiated via N-ethyl-N-nitrosourea (ENU) (described below) exposure 1 week after beginning dox treatment with the exception of lineage A and B (Figure 3 ), which were spontaneous after $6 months dox treatment. Explants were performed under isoflurane-induced anesthesia when a mammary tumor reached 2 3 2 cm (measured using calipers). Approximately 1/3 of the primary tumor was harvested and divided into $2mm x 2mm fragments. Two fragments were used for biopsy histopathology and sequencing analysis. The rest were inserted via a small incision onto both flanks of a number of on-dox, female F 1 FVB/N-C57BL/6J (FVB/B6) host mice. Incisions were closed using surgical clips. All explant tumors were grown on dox until reaching 2 3 2 cm ($30-40 days). One mouse was taken for another generation of explants, and the remaining were removed from dox and monitored twice weekly for regression and relapse. The process was repeated over indicated generations. Time-to-relapse was noted as time between dox withdrawal and first post-withdrawal growth. When relapses reached 2 3 2 cm, explant hosts were necropsied, and relapses were cut using a razorblade into 18 segments. Each segment was stored separately at À80 C until sequencing.
DNA Preparation and Sanger Sequencing
Promega Maxwell 16 Tissue DNA Purification Kit (Promega AS1030) was used to isolate genomic DNA from tail snips and tumor fragments. Primers specific for Apc, b-catenin, and rtTA were used for PCR amplification. Apc primers listed in STAR Methods, b-catenin: 5 0 -GCGTGGACAATGGCTACTCAA, 5 0 -GCGTCAAACTGCGTGGATGG, rtTA: 5 0 -GCCCAGAAGCTAGGTGTAG, 5 0 -CGAATAAGAA GGCTGGCTCTGC. PCR products were purified using a Qiaquick PCR purification kit (28104) or Affimetrix ExoSAP-IT (P/N: 75001). Purified products were Sanger sequenced at Genewiz LLC, South Plainfield, NJ, USA. N-methyl-N-nitrosourea (MNU) or N-ethyl-N-nitrosourea (ENU) were given via intraperitoneal (i.p.) injection (150mg/kg) at 7 weeks of age for select primary mice. For explants, injections were administered when tumors reached 1.5 3 1.5 cm. MNU (Sigma Aldrich N4766) was dissolved in 10mg/mL 0.9% saline immediately prior to injection, and 1g ENU (Sigma Aldrich N3385) was dissolved in 10 mL 95% ethanol and 90mL phosphocitrate buffer (Sigma Aldrich P4809) immediately prior to injection.
Chemical Carcinogenesis
High throughput sequencing
An Apc mmcr PCR product was amplified using primers designed to add the following adapters. 5 0 -TCGTCGGCAGCGTCAGATGTG TATAAGA GACAGACAGAAAGTACTCCAGACGGG-3 0 , and 5 0 -GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGGCTTGGCG TGAT GACTTTG-3 0 . Followed Illumina 16S Metagenomic Sequencing Library Preparation Protocol for clean-up, quantification and normalization. Indices were added using Nextera XT index kit # FC-131-1001. Samples were sequenced using the Illumina Miseq platform, 250 3 250 paired end. Targeted deep sequencing of the amplicon resulted in an average of 287,000 reads per base pair between Apc codons 1492 and 1580. Reads were converted to percentages by dividing the number of reads per base pair at each site by the total number of reads at each site. For example, if a specific site with reference G produced the following: A: 1450 reads, T: 6000 reads G: 242,430 reads, C: 120 reads, it was converted to: A: 0.58%, T: 2.4%, G: 97.0%, C: 0.05%. Next, we estimated error at each site by analyzing the read percentages from the average of two samples known to harbor no mutations, and subtracted that percentage from the experimental samples. Thus, supposing the ''no mutations'' sample at the above hypothetical G site read the following: A: 0.56%, T: 0.64%, G: 98.73%, C: 0.07%, we subtracted those percentages from the experimental sample to estimate the true variant allele frequency as: A: 0.02%, T: 1.76%, G: À1.73%, C: À0.02%. The hypothetical data here indicate a G > T variant in 1.76% of the sample. In this way, we were able to detect mutants with a mutant allele fraction > 0.3%. Ability to detect these low frequency mutants was corroborated by the fact that the mutants identified were nearly always nonsense mutations and consistent with the known ENU mutation pattern.
Quantitative Real Time PCR RNA was purified from mammary glands or tumor fragments using Promega Maxwell 16 Tissue RNA Purification Kit (Promega AS1050) and reverse transcribed using Invitrogen Superscript First Strand Synthesis kit (15080051). We used Taqman Gene Expression Assay Mix (Agilent, Cat#600880) to measure expression of Wnt1 (Applied Biosystems, Mm_01300555_g1). The mix contained unlabeled PCR primers and FAM-labeled probes. Relative quantification PCR (DDCt method) was performed with duplicate reactions using Algilent Technologies Mx3005P detection system and analyzed using Stratagene MxPro Software. Expression levels of Wnt1 were normalized to Gapdh transcript levels (Biosystems 435239E).
Bacterial subcloning PCR product was purified using a Qiaquick PCR purification kit (28104) and subcloned using One Shot TOP 10 chemically competent cells (Invitrogen C404004) and TOPO XL PCR Cloning Kit (Invitrogen 45-0008LT). Multiple individual colonies positive for the insert were harvested and lysed using 10ul water. Second PCR amplification from plasmid DNA was done using the same primers above and purified again. Products were sequenced at Genewiz LLC, South Plainfield, NJ, USA.
Cell suspensions and tumor reconstitution A tumor relapse (composed of R1 and R2 cell populations), as well as the parental iWnt/Apc
Min tumor were made to single cell suspensions. First, $10x10mm fragments of mammary tumor tissue were finely chopped and scraped into a sterile tube. To each, we added 1mL 10X collaganse (diluted in 1X PBS, 63.29mg/5mL) (Sigma C9891), 1mL Hyaluronidase (diluted in 1X PBS, 44.36mg/10mL) (Sigma H3506), and 8 mL DMEM/F12 media. Tissue was incubated for 1 hour at 37 C while slowly shaking, then centrifuged at 550xg for 5 minutes. The pellet was re-suspend in 7mL 0.25% Trypsin-EDTA (GIBCO 15000-054) and shaken vigorously by hand for 1-3 minutes until tissue chunks were broken. Next, the tissue was centrifuged again and the supernatant removed. The pellet was re-suspended in 2mL pre-warmed, sterile-filtered 1X Dispase / Neutral Protease (10mg/mL) (Roche 0492078001) + 0.4 mL 10X DNase (Worthington DNase-DPRF LS006331) + 1.6 mL 1X PBS and shaken by hand for 1-3 minutes. Cells were filtered into 5mL tubes with 40mm filter caps (Falcon cat#352235) and then centrifuged for 5 minutes at 550xg. Finally, pellet was re-suspend in 0.64% NHCl 4 , incubated at room temperature for 3 minutes, then centrifuged at 550xg for 5 minutes and re-suspend in 1X PBS. Cells were counted a hemocytometer, and re-suspend in 50% PBS, 50% Matrigel (BD Biosciences Growth Factor Reduced Matrigel Mix, Cat#356231) at 1,000 cells/mL for mammary gland injections. Mammary glands were exposed via surgical incision, and 10 5 cells in 100mL Matrigel/PBS were injected into intact 3 or 4 mammary fat pads of on-dox, host FVB/B6 female mice. In mixed population injections, cells were injected in a 2:1 admixture (R1:R2 or P:R2, respectively). Growth occurred synchronously and tumors were harvested at 31 days post injection, when multiregion sequencing was feasible for all tumors.
Tamoxifen Tamoxifen (Sigma T5648-1G) was dissolved in corn oil (Sigma C8267) at 20mg/mL. 3 mg was injected intraperitoneally for Cre-mediated recombination.
Confocal Imaging
Snap frozen sections of tumors (mammary or intestine) ($20mm) were cut and mounted on slides. DRAQ5 (Cell Signaling 4084S) was used as a counterstain for far-red fluorescence. Slides were visualized using a Leica SP8 Inverted Confocal Microscope and analyzed using IMARIS Florescence imaging processing software.
Immunohistochemistry
Mammary glands, mammary tumors, and intestinal tumors were fixed with 4% paraformaldehyde for at least 2 hours, imbedded in paraffin, and sectioned. Samples were heated to 65C for 20 minutes in PBS and cooled for 20 minutes at room temperature. They were cleared with 3x 5 minutes incubation in xylene and rehydrated with 2x 1 minute 100% ethanol, 2x 2 minutes 95% ethanol, and 1x 1 minute 70% ethanol, then placed in PBS for 10 minutes. Antigen retrieval was accomplished via incubation in Sodium Citrate Buffer pH 6.0 for 1 hour at 80C. Samples were then cooled for 10 minutes prior to being washed in PBS at room temperature while slowly shaking. The DAKO envision ARK kit (#3954) was utilized for b-catenin immunohistochemistry. Briefly, endogenous peroxidase activity was quenched for 5 minutes at room temperature with peroxidase block. The primary antibody (mouse anti-b-catenin, BD Transduction Laboratories, 610153) was conjugated to a biotinylated secondary antibody for 15 minutes at room temperature. Then, the blocking reagent containing mouse serum was added to bind residual Biotinylation Reagent. The mixture containing the primary antibody, biotinylated secondary antibody, and mouse serum was diluted to a final primary antibody concentration of 1:50 with PBS 0.1% Triton X and incubated overnight at 4C in the dark. The following day, samples were washed for 10 minutes in PBS and incubated with streptavidin peroxidase for 15 minutes at room temperature then washed for 10 minutes in PBS and developed with 3 0 3-diaminobenidine (DAB) + substrate-chromagen for 10 minutes at room temperature. Finally, samples were washed in water for 5 minutes, 95% ethanol 2x 2 minutes, 100% ethanol 2x 2 minutes, and xylene 3x 1 minutes. Samples were then coverslipped and visualized.
QUANTIFICATION AND STATISTICAL ANALYSIS
Student's t test and Log Rank Test were performed using GraphPad Prism 6.04. PCR-amplified products containing the Apc mmcr region then were subjected to both Sanger sequencing and HTS. Subclone maps are depicted linked to relevant region-specific DNA sequencing data. Boxes rendered in the same color mark segments bearing an identical rescue mutation, which presumably indicates repeat sampling of the same RSC. HTS analysis of the upper left segment identified the 1535 G>T rescue mutation detected by Sanger with read counts indicating a high mutant allele fraction (MAF) of 45%. HTS identified no additional mutant alleles, consistent with this segment being predominantly monoclonal. By contrast, whereas Sanger sequencing of the upper right segment detected only a 1538 C>A rescue mutation, HTS analysis detected not only this mutation (44% MAF), but also a minority 1535 G>T allele (1.2% MAF), which likely reflects invading tumor cells from the neighboring subclone. The 1535 G>T allele also was detected by Sanger in all three lung metastases present at relapse. HTS analysis of a representative metastasis detected the 1535 G>T allele, but no additional mutant alleles, consistent with monophyletic seeding of distant disease. Photomicrograph at lower right shows gross appearance of the lung metastases (indicated by arrows) identified at necropsy. L, lung; H, heart. (d-2) relapse is depicted at left. Colored boxes mark segments harboring rescue mutations detected by Sanger sequencing of the Apc mmcr . Hatched boxes mark segments that appear Apc mmcr wild-type by Sanger. Blow-ups show relevant portions of HTS read count data and Sanger chromatograms for each indicated segment. For the blue segment (upper box), both Sanger and HTS sequencing detected only a single mutant allele present at a high MAF, consistent with sampling of a predominantly monoclonal RSC. For the lower segment (hatched box), no mutant alleles were detected by Sanger, whereas 8 distinct nonsense rescue mutations were detected by HTS (MAFs ranging from 0.8-2.1%), consistent with sampling of a polyclonal admixture of RSCs. Figure 3B ). When these tumor segments were subjected to HTS, no additional mutations beyond those identified by Sanger sequencing were detected, consistent with these relapses deriving from only a few RSCs C, D, E. Subclone maps for mutagenexposed relapses. For ENU day-2 relapses, segments found to be Apc mmcr wild-type by Sanger sequencing routinely were polyclonal when assessed by more sensitive mutation detection methods. For example, when tumor segments were themselves subjected to MRS (left-most panels of C), Sanger sequencing of sub-segments yielded numerous additional rescue mutations. Likewise, both NGS analysis and Sanger sequencing of subcloned alleles permitted detection of Apc mmcr mutant subclones that eluded detection by standard Sanger sequencing. When estimating total RSCs-per-relapse, we made a conservative estimate that each uninterrogated Apc mmcr wild-type segment from the ENU day-2 condition harbors two additional RSCs. Therefore, the actual RSCs-per-relapse numbers for ENU day-2 likely exceed those reported in Fig. 4B . from iWnt/Apc +/+ relapses were used to generate mutation spectra for each hit. The mutation spectrum derived from unexposed relapses reorted in Figure 4C is included here for comparison. Evidence for an ENU mutation signature is evident for both Apc hits (compare with Figure 4C ), suggesting both mutations are ENU-induced. 4) . Treatment of this mouse with Tam followed by ENU generated a mammary tumor (MT) and a liver tumor (LT), whose onset presumably depended on Apc CKO to Apc ∆580 conversion. For lanes 5-8, gDNA templates derive from four representative mammary tumor samples whose analysis is reported in the lineage tracing experiment shown in Fig. 7 . Note that the PCR product corresponding to Apc Δ580 becomes undetectable between 2 and 7 days after intiating the trace with Tam, which coincides with dropout of Confetti labeled cells evident by confocal microscopy. NTC, no template control.
